Innovating Works
NFRP-08-2015
NFRP-08-2015: High density uranium fuel and targets for the production of medical radioisotopes
Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility and of the extensive replacement of highly enriched uranium fuel by low enriched one to address nuclear proliferation concerns. This has been at the origin of the European Observatory on the Supply of Medical Radioisotopes[1], created in order to organise the availability of this essential radiopharmaceutical product.
Sólo fondo perdido 0 €
Europeo
Esta convocatoria está cerrada Esta línea ya está cerrada por lo que no puedes aplicar. Cerró el pasado día 17-09-2014.
Se espera una próxima convocatoria para esta ayuda, aún no está clara la fecha exacta de inicio de convocatoria.
Por suerte, hemos conseguido la lista de proyectos financiados!
Presentación: Consorcio Consorcio: Esta ayuda está diseñada para aplicar a ella en formato consorcio.
Número mínimo de participantes.
Esta ayuda financia Proyectos: Objetivo del proyecto:

Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility and of the extensive replacement of highly enriched uranium fuel by low enriched one to address nuclear proliferation concerns. This has been at the origin of the European Observatory on the Supply of Medical Radioisotopes[1], created in order to organise the availability of this essential radiopharmaceutical product.

Research and innovation should be undertaken to support the replacement of highly enriched uranium fuel and targets by low enriched and high density ones. The issue for the fuel is the sufficient performance and safe operation of the reactor, notably for preserving the fuel elements from meltdown, e.g. in using an appropriate conditioning. The issue for the targets is to achieve a sufficient number of fission reactions that produce Molybdenum-99 and to get a high quality pharmaceutical product.

Scope: This research and innovation will focus on developing new kinds of high density uranium fuel and targets bearing in mind their thermal, mechanical and chemical behaviour and their suitability for use in diff... ver más

Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility and of the extensive replacement of highly enriched uranium fuel by low enriched one to address nuclear proliferation concerns. This has been at the origin of the European Observatory on the Supply of Medical Radioisotopes[1], created in order to organise the availability of this essential radiopharmaceutical product.

Research and innovation should be undertaken to support the replacement of highly enriched uranium fuel and targets by low enriched and high density ones. The issue for the fuel is the sufficient performance and safe operation of the reactor, notably for preserving the fuel elements from meltdown, e.g. in using an appropriate conditioning. The issue for the targets is to achieve a sufficient number of fission reactions that produce Molybdenum-99 and to get a high quality pharmaceutical product.

Scope: This research and innovation will focus on developing new kinds of high density uranium fuel and targets bearing in mind their thermal, mechanical and chemical behaviour and their suitability for use in different research reactors. This will involve inter alia the investigation of heat resistance, preserved microstructure, reduced oxidation and thermal fatigue of high density fuel and targets by appropriate coating. Fuel and target fabrication will be studied in view of testing their properties under thermal stress before and after irradiation. International cooperation could be beneficial in this area.

Impact: The cost effective supply of high density and low enriched uranium fuel and targets will allow the more efficient use of research reactors in Europe for the purpose of energy research and the production of medical radioisotopes like Molybdenum-99. This will contribute to the addressing of key challenges of Horizon 2020 in the sectors of energy and health. The principal impact of this action will be the prevention of future crises in the supply of Molybdenum-99.

Type of action: Research and innovation actions.

Additional information: The Commission considers that proposals requesting a contribution from the Euratom of between EUR 4 and 6 million would allow this specific challenge to be addressed appropriately. Nonetheless, this does not preclude submission and selection of proposals requesting other amounts.

[1]     http://ec.europa.eu/energy/nuclear/radiation_protection/medical/doc/observatory_mission.pdf


ver menos

Temáticas Obligatorias del proyecto: Temática principal: Nuclear physics Radiation and nuclear chemistry Nuclear

Características del consorcio

Ámbito Europeo : La ayuda es de ámbito europeo, puede aplicar a esta linea cualquier empresa que forme parte de la Comunidad Europea.
Tipo y tamaño de organizaciones: El diseño de consorcio necesario para la tramitación de esta ayuda necesita de:

Características del Proyecto

Requisitos de diseño: Duración:
Requisitos técnicos: Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility and of the extensive replacement of highly enriched uranium fuel by low enriched one to address nuclear proliferation concerns. This has been at the origin of the European Observatory on the Supply of Medical Radioisotopes[1], created in order to organise the availability of this essential radiopharmaceutical product. Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility and of the extensive replacement of highly enriched uranium fuel by low enriched one to address nuclear proliferation concerns. This has been at the origin of the European Observatory on the Supply of Medical Radioisotopes[1], created in order to organise the availability of this essential radiopharmaceutical product.
¿Quieres ejemplos? Puedes consultar aquí los últimos proyectos conocidos financiados por esta línea, sus tecnologías, sus presupuestos y sus compañías.
Capítulos financiables: Los capítulos de gastos financiables para esta línea son:
Personnel costs.
Los costes de personal subvencionables cubren las horas de trabajo efectivo de las personas directamente dedicadas a la ejecución de la acción. Los propietarios de pequeñas y medianas empresas que no perciban salario y otras personas físicas que no perciban salario podrán imputar los costes de personal sobre la base de una escala de costes unitarios
Purchase costs.
Los otros costes directos se dividen en los siguientes apartados: Viajes, amortizaciones, equipamiento y otros bienes y servicios. Se financia la amortización de equipos, permitiendo incluir la amortización de equipos adquiridos antes del proyecto si se registra durante su ejecución. En el apartado de otros bienes y servicios se incluyen los diferentes bienes y servicios comprados por los beneficiarios a proveedores externos para poder llevar a cabo sus tareas
Subcontracting costs.
La subcontratación en ayudas europeas no debe tratarse del core de actividades de I+D del proyecto. El contratista debe ser seleccionado por el beneficiario de acuerdo con el principio de mejor relación calidad-precio bajo las condiciones de transparencia e igualdad (en ningún caso consistirá en solicitar menos de 3 ofertas). En el caso de entidades públicas, para la subcontratación se deberán de seguir las leyes que rijan en el país al que pertenezca el contratante
Madurez tecnológica: La tramitación de esta ayuda requiere de un nivel tecnológico mínimo en el proyecto de TRL 5:. Los elementos básicos de la innovación son integrados de manera que la configuración final es similar a su aplicación final, es decir que está listo para ser usado en la simulación de un entorno real. Se mejoran los modelos tanto técnicos como económicos del diseño inicial, se ha identificado adicionalmente aspectos de seguridad, limitaciones ambiéntales y/o regulatorios entre otros. + info.
TRL esperado:

Características de la financiación

Intensidad de la ayuda: Sólo fondo perdido + info
Fondo perdido:
0% 25% 50% 75% 100%
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme
3.2 Guide to the submission and evaluation process
 
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Standard evaluation form
Annotated Model Grant Agreement
 
Additional provisions:
Horizon 2020 budget flexibility
Classified information
 
Open access must be gr...
Please read carefully all provisions below before the preparation of your application.
List of countries and applicable rules for funding: described in part A of the General Annexes of the General Work Programme.
 
Eligibility and admissibility conditions: described in part B and C of the General Annexes of the General Work Programme
 
Evaluation
3.1  Evaluation criteria and procedure, scoring and threshold: described in part H of the General Annexes of the General Work Programme
3.2 Guide to the submission and evaluation process
 
Proposal page limits and layout: Please refer to Part B of the standard proposal template.
 
Indicative timetable for evaluation and grant agreement:
Information on the outcome of one-stage evaluation: maximum 5 months from the final date for submission.
Signature of grant agreements: maximum 3 months from the date of informing successful applicants.
Provisions, proposal templates and evaluation forms for the type(s) of action(s) under this topic:
Research and Innovation Action:
Specific provisions and funding rates
Standard proposal template (administrative forms and structure of technical annex)
Standard evaluation form
Annotated Model Grant Agreement
 
Additional provisions:
Horizon 2020 budget flexibility
Classified information
 
Open access must be granted to all scientific publications resulting from Horizon 2020 actions, and proposals must refer to measures envisaged. Where relevant, proposals should also provide information on how the participants will manage the research data generated and/or collected during the project, such as details on what types of data the project will generate, whether and how this data will be exploited or made accessible for verification and re-use, and how it will be curated and preserved.
 
Garantías:
No exige Garantías
No existen condiciones financieras para el beneficiario.

Información adicional de la convocatoria

Efecto incentivador: Esta ayuda tiene efecto incentivador, por lo que el proyecto no puede haberse iniciado antes de la presentación de la solicitud de ayuda. + info.
Respuesta Organismo: Se calcula que aproximadamente, la respuesta del organismo una vez tramitada la ayuda es de:
Meses de respuesta:
Muy Competitiva:
No Competitiva Competitiva Muy Competitiva
No conocemos el presupuesto total de la línea
Minimis: Esta línea de financiación NO considera una “ayuda de minimis”. Puedes consultar la normativa aquí.

Otras ventajas

Sello PYME: Tramitar esta ayuda con éxito permite conseguir el sello de calidad de “sello pyme innovadora”. Que permite ciertas ventajas fiscales.
NFRP-2014-2015 High density uranium fuel and targets for the production of medical radioisotopes Scope:Specific Challenge: A shortage of Molybdenum-99 has occurred mainly as a result of the low availability of research reactor facility a...
Sin info.
NFRP-2019-2020-13 Research roadmap for medical applications of ionising radiation
en consorcio: Specific Challenge:Nuclear and ionising radiation technologies have a central place in modern medicine, saving lives and improving the quali...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-14 Improving low-dose radiation risk appraisal in medicine
en consorcio: Specific Challenge:Nowadays medical care extensively uses ionising radiation for diagnostic and therapy. Together with natural radiation, me...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-10 Developing pre-disposal activities identified in the scope of the European Joint Programme in Radioactive Waste Management
en consorcio: Specific Challenge:In Europe, the challenges in the field of radioactive waste management (RWM) include: To improve, innovate and develop s...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-03 Safety margins determination for design basis-exceeding external hazards
en consorcio: Specific Challenge:EU nuclear plants need to demonstrate compliance with evolving and stringent safety requirements. These research actions...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de
NFRP-2019-2020-05 Support for safety research of Small Modular Reactors
en consorcio: Specific Challenge: Small Modular Reactors (SMRs) are considered as a reasonable option to cover future energy needs and applications like e...
Cerrada hace 5 años | Próxima convocatoria prevista para el mes de